Stemgent (Cambridge, MA) a commercial-stage biopharmaceutical company focused on stem cell reagents and tools for stem cell researchers, closed a $6.3M Series C financing. Participants include HealthCare Ventures and Morganthaler Partners.

Promedior (Malvern, PA) a clinical stage biotechnology company developing pentraxin therapeutics for fibroproliferative diseases, closed a $21.5M Series D financing. Participants include Fibrotec Ventures, Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group.

Radius Health (Cambridge, MA) a clinical-stage biopharmaceutical company focused on osteoporosis and women’s health, closed a $21.4M Series C financing, bringing the total round to $91M. Participants include Brookside Capital, Saints Capital, Nordic Bioscience, Ipsen Pharma, MPM Capital, BB Biotech Ventures, The Wellcome Trust, HealthCare Ventures and Scottish Widows Investment Partnership.

Sensors for Medicine and Science (Germantown, MD) a commercial-stage device company focused on implantable, long- term continuous glucose monitoring, closed a $54.1M million in Series D financing. Participants include Delphi Ventures, New Enterprise Associates, HealthCare Ventures, Anthem Capital and Greenspring Associates.

PathoGenetix (Woburn, MA) a development-stage sequencing company focused on simultaneous identification and characterization of bacterial strains in a single test, closed a $7.5M Series B financing, bringing the total round to $11.5M. Participants include Ascension Health Ventures, Excel Venture Management, CB Health Ventures and HealthCare Ventures.

nanoMR (Albuquerque, NM) a development stage medical device focused on a immunomagnetic capture system for the blood culture market, closed a $13M Series B financing. Participants include Excel Venture Management, Healthcare Ventures, vSpring Capital, Dow Chemical Company and Sun Mountain Capital. Thanx for your patience as we catch-up.

Cleveland Heartlab (Cleveland, OH) a commercial-stage specialty clinical laboratory and disease management company focused on assessing cardiovascular risk, closed a $18.4M Series B financing. Participants include Excel Venture Management and HealthCare Ventures. Thanx for your patience as we catch-up.

PathoGenetiX (Woburn, MA) a development-stage diagnostic company focused on the identification of pathogenic bacterial strains, closed a $4M Series B financing. Participants include Excel Venture Management, CB Health Ventures and HealthCare Ventures. Thanx for your patience as we catch-up.

Mosaic Bioscience (Boulder, CO) a development-stage synthetic materials company focused on tissue and bone regeneration, closed a $1M Series A financing. Participants include Morgenthaler, HealthCare Ventures and High Country Venture.

Tensha Therapeutics (Cambridge, MA) a preclinical-stage pharmaceutical company focused on midline carcinoma, acute myeloid leukemias and multiple myeloma, closed a $15M Series A financing. Participants include HealthCare Ventures.

Theraclone Sciences (Seattle, WA) a preclinical-stage biopharmaceutical company focused on monoclonal antibodies for infectious disease and inflammation, closed a $10.6M Series B, bringing the total round to $41M. Participants include Arch Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo.

TetraLogic Pharmaceuticals (Malvern, PA) a clinical-stage pharmaceutical company developing novel small molecule drugs to treat cancer, closed a $6M Series C financing bringing the total round to $43M. Participants include Nextech Invest, Clarus Ventures, Hatteras Venture Partners, Pfizer Venture Investments, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures, Vertical Group and Amgen Ventures.

Radius Health (Cambridge, MA) a clinical-stage biopharmaceutical company focused on osteoporosis and women’s health, closed a $66M Series C financing. Participants include Brookside Capital, Saints Capital, Nordic Bioscience, Ipsen Pharma, MPM Capital, BB Biotech Ventures, The Wellcome Trust, HealthCare Ventures and Scottish Widows Investment Partnership.